India’s controversial compensation rules could lead to clinical trials "standstill"
This article was originally published in SRA
India's recently gazetted trial compensation norms go against the very "tenets of science" putting at risk the future of the country as a favorable destination for such studies, according to a clutch of industry pundits1.
You may also be interested in...
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Pharma appears to be treading carefully when it comes to research preprints but COVID-19 has spotlighted the role of these pre-peer-reviewed papers during public health emergencies.